Volpe F, Nappi C, Piscopo L, Zampella E, Mainolfi CG, Ponsiglione A, et al. Emerging role of nuclear medicine in prostate cancer: current state and future perspectives. Cancers. 2023;15:4746.

Article  CAS  Google Scholar 

Galletti G, Leach BI, Lam L, Tagawa ST. Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer. Cancer Treat Rev. 2017;57:16–27.

Article  CAS  Google Scholar 

Klain M, Gaudieri V, Petretta M, Zampella E, Storto G, Nappi C, et al. Combined bone scintigraphy and fluorocholine PET/computed tomography predicts response to radium-223 therapy in patients with prostate cancer. Future Sci OA. 2021;7(8):FSO719.

Article  CAS  Google Scholar 

Elting LS, Cooksley C, Bekele BN, Frumovitz M, Avritscher EB, Sun C, Bodurka DC. Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants. Cancer. 2006;106:2452–8.

Article  Google Scholar 

Kuppen MC, Westgeest HM, Van Der Doelen MJ, Van Den Eertwegh AJ, Coenen JL, Aben KK, et al. Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer. Future Oncol. 2020;16:1371–84.

Article  CAS  Google Scholar 

Minner S, Wittmer C, Graefen M, Salomon G, Steuber T, Haese A, et al. High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. Prostate. 2011;71:281–8.

Article  Google Scholar 

Kabasakal L, AbuQbeitah M, Aygün A, Yeyin N, Ocak M, Demirci E, Toklu T. Pre-therapeutic dosimetry of normal organs and tissues of 177 Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:1976–83.

Article  CAS  Google Scholar 

Kratochwil C, Giesel FL, Stefanova M, Benešová M, Bronzel M, Afshar-Oromieh A, et al. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617. J Nucl Med. 2016;57:1170–6.

Article  CAS  Google Scholar 

Emmett L, Willowson K, Violet J, Shin J, Blanksby A, Lee J. Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. J Med Radiat Sci. 2017;64:52–60.

Article  Google Scholar 

Piscopo L, Zampella E, Pellegrino S, Volpe F, Nappi C, Gaudieri V, et al. Diagnosis, management and theragnostic approach of gastro-entero-pancreatic neuroendocrine neoplasms. Cancers. 2023;15:3483.

Article  CAS  Google Scholar 

Zang J, Wang G, Zhao T, Liu H, Lin X, Yang Y, et al. A phase 1 trial to determine the maximum tolerated dose and patient-specific dosimetry of [177Lu] Lu-LNC1003 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2023. https://doi.org/10.1007/s00259-023-06470-3.

Article  Google Scholar 

Wang Z, Tian R, Niu G, Ma Y, Lang L, Szajek LP, et al. Single low-dose injection of Evans blue modified PSMA-617 radioligand therapy eliminates prostate-specific membrane antigen positive tumors. Bioconjug Chem. 2018;29:3213–21.

Article  CAS  Google Scholar 

Zang J, Fan X, Wang H, Liu Q, Wang J, Li H, et al. First-in-human study of 177 Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46:148–58.

Article  CAS  Google Scholar 

Wen X, Xu P, Zeng X, Liu J, Du C, Zeng X, et al. Development of [177Lu] Lu-LNC1003 for radioligand therapy of prostate cancer with a moderate level of PSMA expression. Eur J Nucl Med Mol Imaging. 2023;50:2846–60.

Article  CAS  Google Scholar 

Bianco D, Nappi C, Piscopo L, Volpe F, Manganelli M, Volpicelli F, et al. Initial testing of an approximated, fast calculation procedure for personalized dosimetry in radionuclide therapy based on planar whole-body scan and Monte-Carlo specific dose rates from the OpenDose project. Life. 2022;12:1303.

Article  CAS  Google Scholar 

Delker A, Schleske M, Liubchenko G, Berg I, Zacherl MJ, Brendel M, et al. Biodistribution and dosimetry for combined [177Lu]Lu-PSMA-I&T/[225Ac]Ac-PSMA-I&T therapy using multi-isotope quantitative SPECT imaging. Eur J Nucl Med Mol Imaging. 2023;50:1280–90.

Article  CAS  Google Scholar 

Alan-Selcuk N, Beydagi G, Demirci E, Ocak M, Celik S, Oven BB, et al. Clinical experience with [225Ac]Ac-PSMA treatment in patients with [177Lu]Lu-PSMA-refractory metastatic castration-resistant prostate cancer. J Nucl Med. 2023;64:1574–80.

Article  Google Scholar